...
首页> 外文期刊>Journal of Drug Delivery and Therapeutics >FORMULATION DEVELOPMENT AND EVALUATION OF pH TRIGGERED IN SITU OPHTHALMIC GEL OF BESIFLOXACIN HYDROCHLORIDE
【24h】

FORMULATION DEVELOPMENT AND EVALUATION OF pH TRIGGERED IN SITU OPHTHALMIC GEL OF BESIFLOXACIN HYDROCHLORIDE

机译:盐酸贝西沙星原位眼药凝胶引发pH的配方开发与评价

获取原文

摘要

The aim of the present work was to formulation and evaluation of pH Triggered in-situ Ophthalmic Gel of Besifloxacin Hydrochloride to overcome the drawbacks obtained by conventional eye drop. There are two independent variables were used i.e. Carbopol 934 and HPMC K100. Carbopol 934 were used as gelling agent and HPMC K100 were used as bioadhesive polymer. Besifloxacin Hydrochloride shows activity against a wide range of?Gram-positive?and?negative ocular pathogens: examples are Corynebacterium pseudodiphtheriticum,?Moraxella lacunata,?Staphylococcus aureus,?Staphylococcus epidermidis,?Streptococcus pneumoniae?and?Streptococcus salivarius. The in situ gelling system involves sol-to-gel transition in the cul-de-sac upon instillation to avoid pre corneal elimination. The formulations were prepared by 32 factorial design. The prepared formulations were evaluated for clarity, pH, viscosity, Bioadhesive strength of gel, gel strength gel, Drug Content, In-vitro Drug Release Study, Antibacterial Activity, Isotonicity Evaluation, HET-CAM Test and stability studies. The drug content was in the range of 97-99.57 %. Formulation F5 selected as optimized on the basis of evaluation. It shows highest drug release upto 8hrs. It shows good antibiotic activity against Staphylococcus aureus. The optimized formulation was isotonic with blood cells. It passes sterility test. The optimized formulation passes the ocular irritancy test i.e. HET-CAM Test. The formulation kept for the stability study for 3 months. Short term stability study indicates that room temperature 400±20 was appropriate storage condition for formulations.
机译:本工作的目的是配制和评估盐酸贝西沙星的pH触发原位眼用凝胶,以克服常规滴眼剂所带来的缺点。使用了两个自变量,即Carbopol 934和HPMC K100。 Carbopol 934用作胶凝剂,HPMC K100用作生物粘合剂聚合物。盐酸贝西沙星显示出对多种革兰氏阳性和阴性眼病原体的活性:例如假双肺棒状杆菌,空肠莫拉菌,金黄色葡萄球菌,表皮葡萄球菌,肺炎链球菌和链球菌。原位胶凝系统涉及在滴注时在死胡同中进行溶胶-凝胶转变,以避免角膜预先消除。通过32阶因子设计制备制剂。评价制备的制剂的透明度,pH,粘度,凝胶的生物粘附强度,凝胶强度凝胶,药物含量,体外药物释放研究,抗菌活性,等渗性评估,HET-CAM测试和稳定性研究。药物含量在97-99.57%的范围内。配方F5在评估的基础上选择为最佳。它显示了长达8小时的最高药物释放。对金黄色葡萄球菌显示出良好的抗生素活性。优化的配方与血细胞等渗。通过无菌测试。优化的配方通过了眼刺激性测试,即HET-CAM测试。该制剂保持稳定性研究3个月。短期稳定性研究表明,室温400±20是制剂的合适储存条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号